Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents

Investigative Radiology

Volumn 44, Issue 4, 2009, Pages 226-233

  Pietsch, Hubertus ^a   Lengsfeld, Philipp ^a   Steger Hartmann, Thomas ^a   Löwe, Andrea ^a   Frenzel, Thomas ^a   Hütter, Joachim ^a   Sieber, Martin A ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Complex stability; Gadolinium (Gd) retention; Gd based contrast agents; Nephrogenic systemic fibrosis; Renal impairment

Indexed keywords

CONTRAST MEDIUM; GADOBUTROL; GADODIAMIDE; GADOLINIUM PENTETATE; GADOVERSETAMIDE;

ANALYTIC METHOD; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; ATOMIC EMISSION SPECTROMETRY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG CLEARANCE; DRUG RETENTION; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; NEPHRECTOMY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SKIN; SKIN BIOPSY;

ANIMALS; CONTRAST MEDIA; GADOLINIUM; MALE; NEPHROGENIC FIBROSING DERMOPATHY; RATS; RATS, WISTAR; RENAL INSUFFICIENCY; SKIN;

EID: 67651115687     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e3181998eb7     Document Type: Article

References (38)

1. Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet. 2000;356:1000-1001.
2. Deo A, Fogel M, Cowper SE. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol. 2007;2:264-267.
3. Lauenstein TC, Salman K, Morreira R, et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging. 2007;26:1198-1203.
4. Shabana WM, Cohan RH, Ellis JH, et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol. 2008;190:736-741.
5. Sieber MA, Lengsfeld P, Walter J, et al. Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand. J Magn Reson Imaging. 2008;27:955-962.
6. Sieber MA, Pietsch H, Walter J, et al. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadoliniumbased contrast media. Invest Radiol. 2008;43:65-75.
7. Weinmann HJ, Laniado M, Mutzel W. Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. Physiol Chem Phys Med NMR. 1984;16:167-172.
8. VanWagoner M, O'Toole M, Worah D, et al. A phase I clinical trial with gadodiamide injection, a nonionic magnetic resonance imaging enhancement agent. Invest Radiol. 1991;26:980-986.
9. Joffe P, Thomsen HS, Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol. 1998;5: 491-502.
10. Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol. 2008;18:2164-2173.
11. Gretz N, Waldherr R, Strauch M. In: Gretz N, Strauch M, eds. The Remnant Kidney Model. Basel, Switzerland: Karger; 1993:1-28.
12. Kliem V, Johnson RJ, Alpers CE, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int. 1996;49:666-678.
13. Caravan P, Ellison JJ, McMurry TJ, et al. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999;99: 2293-2352.
14. Schmitt-Willich H. Stability of linear and macrocyclic gadolinium based contrast agents. Br J Radiol. 2007;80:581-582; Author reply 584-585.
15. Pietsch H, Lengsfeld P, Jost G, et al. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium based contrast agents. Eur Radiol. 2009 Jan, 24 (Epub ahead of print).
16. Deleted in proof.
17. Deleted in proof.
18. Skelly Frame EM, Uzgiris EE. Gadolinium determination in tissue samples by inductively coupled plasma mass spectrometry and inductively coupled plasma atomic emission spectrometry in evaluation of the action of magnetic resonance imaging contrast agents. Analyst. 1998;123:675-679.
19. Thomas RA. Beginner's Guide to ICP-MS. London, UK: CRC Press Inc; 2001. 38-42.
20. Prince MR, Zhang H, Morris M, et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology. 2008;248:807-816.
21. Wertman R, Altun E, Martin DR, et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology. 2008;248:799-806.
22. Schuhmann-Giampieri G, Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol. 1991;26:975-979.
23. Kuhlmann U, Walb D, Luft FC. Nephrologie. Stuttgart, Germany: Georg Thieme Verlag; 2003.
24. Frenzel T, Lengsfeld P, Schirmer H, et al. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008;43:817-828.
25. Abraham JL, Thakral C, Skov L, et al. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol. 2008;158:273-280.
26. Broome DR. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol. 2008;66:230-234.
27. High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007;56:710-712.
28. Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. 2007;56:27-30.
29. Abraham JL, Thakral C. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. Eur J Radiol. 2008;66:200-207.
30. Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol. 2006;17:2359-2362.
31. Khurana A, Runge VM, Narayanan M, et al. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol. 2007;42:139-145.
32. Herborn CU, Honold E, Wolf M, et al. Clinical safety and diagnostic value of the gadolinium chelate gadoterate meglumine (Gd-DOTA). Invest Radiol. 2007;42:58-62.
33. Rydahl C, Thomsen HS, Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol. 2008;43:141-144.
34. Penfield JG, Reilly RF. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents? Semin Dial. 2008;21:129-134.
35. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging. 1990;8:467-481.
36. Imura H, Choppin G, Cacheris W, et al. Thermodynamics and NMR studies of DTPA-bis(methoxyethylamide) and its derivatives. Protonations and complexation with Ln(III). Inorganica Chim Acta. 1997;258:227-236.
37. Schmitt-Willich H, Brehm M, Ewers CL, et al. Synthesis and Physicochemical Characterization of a New Gadolinium Chelate: The liver-specific magnetic resonance imaging contrast agent Gd-EOB-DTPA. Inorg Chem. 1999; 38:1134-1144.
38. Port M, Idée JM, Medina C, Robic C, et al. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals. 2008;21(4):469-490.